© 1997 American Heart Association, Inc.
Articles |
Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease
From Cardiovascular Genetics, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, (P.N.H., L.L.W., S.C.H., R.D.W.); the Department of Pathology, University of Utah School of Medicine, Associated Regional and University Pathologists (L.L.W.); Intermountain Health Care and University of Utah School of Medicine, (B.C.J.); and the Cardiology Division, LDS Hospital, and University of Utah School of Medicine (G.M.V.), Salt Lake City, Utah.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract An interaction between high plasma lipoprotein(a) [Lp(a)], unfavorable plasma lipids, and other risk factors may lead to very high risk for premature CAD. Plasma Lp(a), lipids, and other coronary risk factors were examined in 170 cases with early familial CAD and 165 control subjects to test this hypothesis. In univariate analysis, relative odds for CAD were 2.95 (P<.001) for plasma Lp(a) above 40 mg/dL. Nearly all the risk associated with elevated Lp(a) was found to be restricted to persons with historically elevated plasma total cholesterol (6.72 mmol/L [260 mg/dL] or higher) or with a total/HDL cholesterol ratio >5.8. Nonlipid risk factors were also found to at least multiply the risk associated with Lp(a). When Lp(a) was over 40 mg/dL and plasma total/HDL cholesterol >5.8, relative odds for CAD were 25 (P=.0001) in multiple logistic regression. If two or more nonlipid risk factors were also present (including hypertension, diabetes, cigarette smoking, high total homocysteine, or low serum bilirubin), relative odds were 122 (P<1x10-12). The ability of nonlipid risk factors to increase risk associated with Lp(a) was dependent on at least a mildly elevated total/HDL cholesterol ratio. In conclusion, high Lp(a) was found to greatly increase risk only if the total/HDL cholesterol ratio was at least mildly elevated, an effect exaggerated by other risk factors. Aggressive lipid lowering in those with elevated Lp(a) therefore appears indicated.
Key Words: lipoprotein(a) • risk factors • genetics • coronary heart disease • case-control studies
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Lipoprotein(a) [Lp(a)] refers to particles formed by the covalent binding of the glycoprotein apoprotein(a) to apoprotein B of LDL by disulfide linkage. Increased plasma concentration of Lp(a) has been associated with increased risk for premature coronary disease in numerous retrospective case-control studies among white subjects1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 and in most prospective studies,47 48 49 50 51 52 53 54 55 56 57 58 59 with three notable exceptions.56 60 61 High Lp(a) is apparently not a risk factor among blacks40 62 or, in some studies, among the elderly.10 11 46 63 High Lp(a) has been found to be predictive of more rapid progression of coronary artery disease (CAD) in serial angiograms.64 65 66 It was also associated with more rapid occlusion of coronary bypass grafts in one study67 but not in another.68 A higher frequency of restenosis after angioplasty in those with high Lp(a) has been noted in most69 70 71 72 73 74 75 but not all studies,35 and endothelial dysfunction has been associated with high Lp(a).76 Risk for stroke12 37 77 or carotid atherosclerosis78 79 and peripheral vascular disease80 81 82 is increased in those with high Lp(a). In children, high Lp(a) is found more frequently in those with a positive family history of coronary disease, at least among whites.83 84 85 86 87
In most of these studies, simple univariate relative odds for CAD have been modest, usually 2 to 4, when Lp(a) is above 30 to 40 mg/dL. In contrast, the risk associated with high Lp(a) has been reported to be much higher in persons with familial hypercholesterolemia.16 20 Yet, an elevated Lp(a) imparted little excess risk among participants of the Physicians Health Study, a group with relatively low serum cholesterol concentrations.61 Furthermore, Maher et al,88 found that in persons with a 10% or greater reduction in LDL cholesterol during a vigorous lipid-lowering intervention, Lp(a) was not predictive of atherosclerosis progression or CAD events (only 9% incidence of new events in those with high Lp(a) and at least 10% LDL reduction), while in those with little change in LDL, Lp(a) remained a strong predictor of progression and events (with a 39% incidence in those with high Lp(a) and <10% LDL reduction). Lp(a) concentration was unaffected by this intervention, consistent with other studies using most cholesterol-lowering agents and observations that plasma Lp(a) levels are normally determined almost entirely by genetic factors at the apo(a) locus.89 90 These findings led to the hypothesis that Lp(a) is primarily a risk factor when serum cholesterol or LDL cholesterol is elevated. Results from several observational and intervention studies were consistent with this hypothesis when, in meta-analysis, relative odds reported in each study were plotted against average study LDL cholesterol levels.91 Nevertheless, few studies have examined this issue directly,9 27 78 and none have examined potential interactions between Lp(a) and nonlipid risk factors.
We have measured plasma Lp(a) concentration, lipids, and other cardiovascular risk factors in patients with early familial coronary disease and control subjects. Nearly all the excess risk associated with Lp(a) was found among those with currently or historically elevated plasma total cholesterol concentration or in those with an increased ratio of total/HDL cholesterol, supporting the hypothesis that plasma lipid levels strongly influence risk from high Lp(a). In addition, several other nonlipid risk factors were found to markedly increase the risk associated with high Lp(a), again dependent on the presence of a moderately high total/HDL cholesterol ratio.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Participants
Early familial CAD cases included 124 men and 46 women who had survived a myocardial infarction, percutaneous transluminal angioplasty, or coronary artery bypass grafting by age 55 for men or age 65 for women. Patients were seen at least 6 months after their acute event. Each of these cases had a sibling confirmed to have early CAD by the same definition. Only unrelated CAD cases were used in the present study. These were selected as the sibling with the earliest onset of CAD in families with multiple screened siblings.
Control subjects included 85 men and 80 women who were ascertained either from a random population sampling (35% of control subjects) or who were spouses of hypertensive siblings who had participated in previous studies in our clinic (65% of control subjects). The former population was selected randomly by computer from a database of families collected as part of the Family Health Tree program, an ongoing collaboration between Cardiovascular Genetics, the Utah Department of Health, and area high schools.92 93 High school students, with the help of their parents, collect health information on family members. The data are computerized and scored for familial disease tendency. Control subjects were selected randomly from the parent generation. Other samples identified from Family Health Trees have been further studied and confirmed to be representative of the Utah population.94 Hypertensive probands whose spouses were used as control subjects were selected for prior studies because they and one or more of their siblings had hypertension onset before age 60.95 All screened spouses were used as control subjects for this study. Comparability of the two groups of control subjects was tested. There were no significant differences for any cardiovascular risk factor between the two control groups, except for a slightly higher plasma total cholesterol among the spouses of hypertensive siblings (P=.05). Since a slightly higher serum cholesterol level could only provide a more conservative comparison with the early familial coronary cases, the two control groups were combined for all further analyses.
In this report, all available cases and control subjects were used. In prior studies of this group, we had constrained the age range to 38 to 68 years so that cases and control subjects might be more completely overlapping in age (these studies also provide justification for including homocyst(e)ine [H(e)] and bilirubin as risk factors in the present study).96 97 However, since Lp(a) is only slightly increased after menopause in women and is unaffected by age in men,98 we deemed such restriction unnecessary. Nevertheless, we have confirmed all findings reported here using the constrained age range as well. This study was approved by the Institutional Review Board of the University of Utah Medical Center. All subjects signed informed consent before participating.
A participant was considered to have hypertension if taking antihypertensive medication with a prior physician diagnosis of hypertension or if the mean of two supine diastolic blood pressures taken with a Critikon Dynamap automated blood pressure machine was greater than 95 mm Hg. Diabetes was considered present if a prior physician diagnosis had been made or if the fasting serum glucose on screening was >7.77 mmol/L (140 mg/dL). Cigarette smoking was dichotomized into "ever" or "never," with ever smoking defined as having smoked daily for 1 year or more. Many patients had quit after onset of their CAD; hence the designation as ever smoking rather than current and former.
Laboratory Methods
Blood samples were collected in the morning after 12 to 16 hours
of fasting and prepared according to guidelines of the Lipid Research
Clinic's Program Manual of Laboratory
Operations.99 Lipids were measured by a microscale
procedure developed in our laboratory.100 Briefly, HDL was
measured in the supernatant after precipitation of apolipoprotein
B–containing particles with dextran sulfate-MgCl2 and
centrifugation in an Eppendorf microcentrifuge.
Triglyceride-rich lipoproteins, primarily VLDL, were
separated from LDL and HDL by use of a Beckman TL100
ultracentrifuge. The value for VLDL cholesterol was
taken as the measured cholesterol in the top fraction. This
value was compared with the total cholesterol minus the
cholesterol in the bottom fraction containing LDL+HDL and
verified to yield virtually identical results. Cholesterol
and triglycerides in total plasma and subfractions were
measured with a Roche FARA II automated analyzer. Our lipid
laboratory participates in the standardization program of the Centers
for Disease Control in Atlanta, Georgia.
Lp(a) was measured with a commercial enzyme-linked immunosorbent assay that uses a monoclonal antibody linked to a solid phase to trap Lp(a) particles and a polyclonal anti-Lp(a) antibody conjugated with horseradish peroxidase as the reporter antibody (Macra Lp(a) kit, Strategic Diagnostics Inc).101 102 Units refer to whole particle mass per unit volume. The polyclonal anti-Lp(a) used in this assay yields Lp(a) concentrations somewhat higher than an assay using an anti-apoB reporter antibody, the discrepancy being most apparent at Lp(a) concentrations under 10 mg/dL and minimal at values above 10 mg/dL.102 This is in contrast to the underestimation bias at higher Lp(a) concentrations observed for a monoclonal anti-Lp(a) antibody that recognized an epitope on the kringle 4 type 2 repeating subunit.103 In our laboratory, the interassay variation (coefficient of variation) was 6% for samples having over 40 mg/dL Lp(a) and 11% for samples with 18 mg/dL Lp(a). These values are comparable to those reported in the kit documentation. Precision decreased further at lower concentrations with a coefficient of variation of 21% at 2.0 mg/dL Lp(a).
Samples were stored at -70°C using small-volume storage vials that were thawed only once at the time of assay to avoid the differential loss of Lp(a) antigenicity seen at lower storage temperatures.75 104 105 Indeed, an overly long storage time at -20°C has been suggested as an explanation for the lack of association between Lp(a) and coronary disease in the Helsinki Heart Study60 and another Finnish study.56
Total H(e) was measured after reduction of disulfide bonds and detection of released homocysteine by high-pressure liquid chromatography as described by Malinow et al106 with minor modifications.107
Statistical Analysis
The SAS Statistical Software Package was used for data
analysis (SAS Institute, Inc, Cary, NC). Statistical
analyses on triglycerides were done after
logarithmic transformation. Statistical tests included Student's
t test, 
2, Fisher's exact test,
Pearson's correlation, and stepwise multiple logistic regression. The
Wilcoxon rank sum test was used to compare Lp(a) values in
cases and control subjects. Calculation of pooled relative odds after
stratification by gender was performed by the Mantel-Haenszel method as
described by Rothman.108
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clinical characteristics of unrelated early familial coronary cases and control subjects are shown in Table 1
. The male cases were, on average, 5
years older, while age difference in women was about 15 years. In
addition, the prevalence rates of hypertension and diabetes were
markedly higher in both male and female cases than control subjects.
Case women had significantly higher body mass index (BMI, as
kg/m2), blood pressures, plasma total
cholesterol, measured LDL cholesterol, VLDL
cholesterol, triglycerides, and H(e) levels
than control women. Plasma HDL cholesterol and bilirubin
were significantly lower. Among men, similar relationships were seen,
except that BMI, blood pressures, and total and measured LDL
cholesterol were not significantly higher in cases than
control subjects. Measured plasma LDL cholesterol levels
were not different in male cases compared with control subjects,
probably because of treatment. About half of the cases were being
treated with diet and/or medication for high cholesterol
(with about one third of all cases taking lipid-lowering medication),
while fewer than 8% of the control subjects were on a diet and none
were taking lipid-lowering medication. Maximum total
cholesterol levels (see below) were significantly higher in
cases of both genders.
|
To estimate the effect of increasing Lp(a) on risk, cases and control
subjects were categorized by plasma Lp(a) quintile (based on the
control population), and relative odds were calculated. Control
population percentile levels are given in Table 2. The Mantel-Haenszel test for trend was
significant in men (P=.045) but failed reach significance in
women (P=.3). Pooled estimates of relative odds after
stratification by gender are given in Table 3. Clearly, most of the excess risk
associated with Lp(a) was observed in the highest quintile (ie, above
the 80th percentile). Relative odds for Lp(a) above 40 mg/dL
(roughly the 90th percentile in control subjects) was 2.95
(P=.001) in univariate analysis.
|
|
Risks associated with Lp(a) at different lipid levels were then
examined. Two-way classification by screened plasma total
cholesterol and Lp(a) is shown in Table 4. In this analysis, only a
slight trend for greater effects of Lp(a) among those with higher
measured total cholesterol was observed. Classification by
measured LDL cholesterol at the time of screening showed
almost identical trends (data not shown). Classification by
total/HDL cholesterol showed stronger evidence for
interaction. However, the 13.4-fold increase in risk among those with
plasma Lp(a) >40 mg/dL and total/HDL
cholesterol >5.8 would also be consistent with a
multiplicative effect between these two
variables.
|
Many of the cases were on lipid-lowering therapy at the time of screening. Most patients treated for lipids began lipid treatment after their coronary events. Historical lipid levels would therefore be expected to be more closely associated with risk than levels measured at the time of screening. To examine this hypothesis, historical maximum cholesterol levels were estimated. The historical maximum cholesterol was taken as the maximum of either the reported prior highest plasma cholesterol level (from questionnaires filled out by participants), the measured total cholesterol level at the time of screening, or the measured total cholesterol level multiplied by 1.2 for those currently taking cholesterol-lowering medication. The 20% adjustment was considered conservative given that many of those treated were taking statin medications and were also following cholesterol-lowering diets. Among the 170 cases, 96 provided a prior highest cholesterol value on their questionnaires (48 of 56 on lipid-lowering medication did so). The actual maximum cholesterol used was the currently measured cholesterol for 79 cases, the historically high cholesterol for 67 cases, and the adjusted high cholesterol for 24 cases. Only 11 of 165 control subjects provided a prior highest cholesterol value on their questionnaires and in five instances it was higher than the measured cholesterol level. The total cholesterol measured at screening among the 48 patients taking lipid-lowering medication who also reported a historical high cholesterol was 5.81±1.06 mmol/L (225±41 mg/dL) (mean±SD) compared with a reported prior maximum total cholesterol of 7.78±1.45 mmol/L (301±56 mg/dL). An adjustment of 20% therefore appeared to be reasonable and conservative.
Risks associated with the various combinations of plasma Lp(a) and
maximum total plasma cholesterol were then calculated as
shown in Table 6. If maximum total
cholesterol level was under 5.68 (220 mmol/L),
an Lp(a) level of 40 mg/dL or greater was associated with only a
small, nonsignificant increase in risk. However, a marked increase in
risk (relative odds=13.8, P=.0000001) was seen among those
with both high cholesterol (above 6.72 mmol/L
[260 mg/dL]), and high Lp(a). In persons with maximum total
cholesterol levels between these values, Lp(a) effects were
intermediate.
|
We then calculated the ratio of plasma maximum total/HDL
cholesterol. The HDL levels at the time of screening were
used in this analysis. Results are shown in Table 7. A strong interactive effect is
apparent with a pooled relative odds estimate of 35 in those with
maximum total/HDL cholesterol ratio above 5.8 and
Lp(a) more than 40 mg/dL compared with those with a maximum
total/HDL cholesterol ratio under 4.5 and Lp(a)
under 15 mg/dL. These results suggest more significant
interaction associated with high Lp(a) when combined with the more
predictive maximum total/HDL cholesterol ratio.
|
Multiple stepwise logistic regression was then performed to examine the
effects of other risk factors on the relationship between plasma Lp(a)
and maximum total/HDL cholesterol ratio. Three dummy
variables (each with possible values 0 or 1) were defined for the
various combinations of high Lp(a) and high maximum total
cholesterol/HDL ratio (both high, only maximum
total/HDL cholesterol high, only Lp(a) high). Other
risk factors included in the model were age, gender, BMI, cigarette
smoking, hypertension, diabetes, and triglycerides (natural
log transformed). Results are given in Table 8. As in the stratified analysis
above, multiple stepwise logistic regression suggested a much stronger
risk associated with high Lp(a) if maximum total/HDL
cholesterol ratio was also high, with relative odds of 25.1
(P=.0001) compared with a nonsignificant risk for high Lp(a)
if maximum plasma total cholesterol was <5.8. Similar
results were found when plasma bilirubin and total H(e) were entered
into the regression, when the analysis was restricted to
persons 38 to 68 years of age, or when only reported maximum plasma
total cholesterol levels were used without adjustment for
drug treatment (results not shown).
|
When continuous levels of maximum total/HDL cholesterol ratio and Lp(a) were examined in multiple logistic regression without an interaction term, Lp(a) entered sixth (behind age, cigarette smoking, maximum total/HDL cholesterol ratio, diabetes, and hypertension), with relative odds of 2.1 associated with a 40 mg/dL increase (P=.015). However, when an interaction term between continuous levels of Lp(a) and maximum total/HDL cholesterol was entered into the regression, the interaction term and maximum total/HDL cholesterol ratio entered, while Lp(a) alone did not, suggesting that most if not all the risk attributable to Lp(a) occurred in conjunction with an elevated maximum total/HDL cholesterol ratio (results not shown).
We then examined potential interaction between high Lp(a) and other,
nonlipid risk factors as shown in Table 9. The effect of Lp(a) >40 mg/dL
versus <40 mg/dL was examined in the presence or absence of
hypertension, cigarette smoking, elevated homocysteine (above the
sex-specific 90th percentile for control subjects), and low bilirubin
(below the sex-specific 40th percentile for control subjects). Diabetes
was examined together with hypertension, since too few control subjects
were affected to calculate reliable odds estimates. Marked elevations
in risk were seen when high Lp(a) was combined with hypertension, high
H(e), or low bilirubin, with observed relative odds for these
combinations greater than the product of each risk factor alone.
The risk associated with high Lp(a) and cigarette smoking appeared
approximately multiplicative. A multiple logistic model was then
tested, which included age and gender, together with three dummy
variables representing combinations of Lp(a) and other
risk factors (Lp(a) >40 mg/dL with zero to two other risk
factors, Lp(a)=40 mg/dL with three or more other risk factors,
and Lp(a) >40 mg/dL with three or more other risk factors).
Other risk factors included maximum total/HDL
cholesterol ratio >5.8, together with factors listed in
Table 9. The combination of high Lp(a) and three or more other risk
factors was associated with relative odds of 43 (P<.0001),
while for three or more risk factors without high Lp(a), the relative
odds were 13 (P<.0001). High Lp(a) with fewer than three
risk factors did not enter into the regression.
|
To determine whether the results with multiple risk factors were
dependent on lipid levels, the risk associated with high Lp(a) was
calculated for exposure to different numbers of nonlipid risk factors
in the presence or absence of a maximum total/HDL
cholesterol ratio >5.8. Results are shown in Table 10. In this analysis, the
increased risk imparted by high Lp(a) in the presence of nonlipid risk
factors was clearly dependent on an elevation of the maximum
total/HDL cholesterol ratio. Exceedingly high risks
were evident when Lp(a) was >40 mg/dL, maximum total/HDL
cholesterol was >5.8, and two or more nonlipid risk
factors were present (odds ratio=122,
P<1.0x10-12 compared with those
having lower levels of all these factors).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We have observed very high risks (relative odds of 13.8, P=1.0x10-7) associated with a combination of high plasma Lp(a) (>40 mg/dL) and elevated historical maximum total cholesterol concentrations. Even higher risks (relative odds of 35, P<1.0x10-7) were associated with the combination of high Lp(a) and an increased ratio of maximum total/HDL cholesterol (>5.8). These risks were further multiplied by other, nonlipid risk factors, but primarily in the presence of an elevated maximum total/HDL cholesterol ratio. In contrast, a high Lp(a) level without historically high plasma total cholesterol or an elevated maximum total/HDL cholesterol ratio was associated with only a small, nonsignificant increase in risk. The risk associated with a high Lp(a) and high plasma maximum total/HDL cholesterol ratio were more than multiplicative, as shown by a significant interaction in multiple logistic regression analysis. These results corroborate and extend more limited findings from other studies.9 27 88 91 Moreover, this is the first investigation to directly examine potential interactions between Lp(a) and nonlipid risk factors.
Limitations of our study should be considered. In some subsets, because of limited numbers, we were unable to make a strong case for true interaction between Lp(a) and lipids versus a simple multiplicative effect. Also, findings from our study are limited to persons with early familial CAD. Extension of these findings to persons with sporadic early coronary disease and confirmation in larger studies would be of great interest. In any retrospective case-control study, inference to a healthy population requires the assumption that levels of the risk factor (in this case Lp(a) levels) are not affected by the disease in question. Recent studies do indicate that Lp(a) concentration may be increased by a number of inflammatory conditions and that Lp(a) concentration shows low-level correlations with other acute-phase reactants.109 Acute-phase reactants together with Lp(a) are known to rise in the first few days to weeks after a myocardial infarction, but these acute elevations resolve after 1 month.110 111 Because our cases were sampled more than 6 months after any acute event, it seems unlikely that the significant differences in our study (and in most other case-control studies) can be attributed to changes in Lp(a) induced by coronary atherosclerosis. However, to our knowledge, no long-term determinations of prospective change in Lp(a) have been made among those who eventually do or do not develop CAD. Finally, we did not determine Lp(a) genotype and are unable to address the question of genotype-specific risk raised by some authors.112 Nevertheless, the preponderance of evidence strongly suggests increased risk associated with quantitative elevation of plasma Lp(a) concentration. Differences in risk associated with qualitative differences remain more speculative.
Several mechanisms whereby Lp(a) may promote atherosclerosis have been proposed. These include inhibition of clot lysis by Lp(a), leading to a thrombogenic state;113 114 115 increased binding to proteoglycans, thereby promoting increased uptake by macrophages;116 and promotion of smooth muscle cell proliferation by blocking the plasmin-dependent activation of transforming growth factor-ß.117 118 119 Though Lp(a) is, if anything, less subject to oxidation than native LDL,120 oxidized Lp(a) may contribute directly to accumulation of lipid in macrophages.121 122
Our findings provide additional insight into how high Lp(a) may increase coronary disease risk. If Lp(a) itself contributed substantially to the lipid pool in foam cells, one might expect a graded risk that was additive with other lipid risk factors. The striking absence of risk associated with high Lp(a) when total/HDL cholesterol was low speaks against this hypothesis. Alternatively, aggravation of late sequelae such as thrombosis superimposed on preexistent, complicated plaques would be consistent with the dependency of Lp(a)-associated risk on other risk factors. The striking interaction between H(e) and Lp(a) found here is of particular interest in this regard, since increased H(e) is also associated with greater thrombotic risk. This interpretation may also help explain the association of Lp(a) with late sequelae of atherosclerosis in other clinical studies. Examples include more rapid progression of CAD in serial angiograms64 65 66 ; higher Lp(a) levels in myocardial infarction survivors who had infarct-related arteries that remained occluded compared with those with recanalization123 ; and increased 4-year mortality in persons with angiograms showing significant carotid atherosclerosis who also had high Lp(a).124
Our findings may have significant public health implications, especially if confirmed by other studies. High Lp(a) may serve as an important risk factor to identify individuals who would especially benefit from aggressive lipid lowering.
|
|
Acknowledgments |
|---|
This study was supported in part by grants HL47651, HL21088, and HL47466 from the National Heart, Lung, and Blood Institute, Bethesda, Md.
|
Footnotes |
|---|
Reprint requests to Dr Paul N. Hopkins, Cardiovascular Genetics Research Clinic, 410 Chipeta Way, Room 161, Salt Lake City, UT 84108.
Received December 16, 1996; accepted May 8, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Angina of effort and an extra pre-beta lipoprotein fraction. Acta Med Scand. 1972;5531(suppl):6-15.
2. Insull W, Najmi M, Wloedman DA. Plasma pre-ß lipoprotein subfractions in diagnosis of coronary artery disease. Circulation. 1972;45(suppl II):II-170-II-175.
3. Papadopoulas NM, Bedynek JL. Serum lipoprotein patterns in patients with coronary atherosclerosis. Clin Chim Acta. 1973;44:153-157.[Medline] [Order article via Infotrieve]
4. Berg K, Dahlen B, Frick MH. Lp(a) lipoprotein and pre-ß1-lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6:230-235.[Medline] [Order article via Infotrieve]
5. Dahlen G, Berg K, Gillnas T, Ericson C. Lp(a) lipoprotein/pre-beta-lipoprotein in Swedish middle-aged males and patients with coronary heart disease. Clin Chem. 1975;7:334-340.
6.
Frick M, Dahlen G, Berg K, Valle M, Hekali P.
Serum lipids in angiographically assessed coronary
atherosclerosis. Chest. 1978;73:62-65.
7. Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res. 1977;18:331-338.[Abstract]
8. Berg K, Dahlen G, Borreson AL. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin Genet. 1979;16:347-352.[Medline] [Order article via Infotrieve]
9. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257.[Medline] [Order article via Infotrieve]
10.
Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg
AL. Lp(a) lipoprotein as a risk factor for myocardial
infarction. JAMA. 1986;256:2540-2544.
11.
Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA,
Gotto AM. Association of levels of lipoprotein Lp(a), plasma
lipids, and other lipoproteins with coronary artery disease
documented by angiography. Circulation. 1986;74:758-765.
12. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.[Medline] [Order article via Infotrieve]
13. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinci GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1987;38:51-61.
14. Durrington PN, Hunt L, Ishola M, Arrol S, Bhatnagar D. Apolipoproteins(a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988;1:1070-1073.[Medline] [Order article via Infotrieve]
15.
Hoefler G, Harnoncourt F, Paschke E, Mirtl W,
Pfeiffer KH, Kostner GM. Lipoprotein Lp(a): a risk factor for
myocardial infarction.
Arteriosclerosis. 1988;8:398-401.
16. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499.[Abstract]
17. Schwartzkopff W, Schleicher J, Pottins I, Yu S-B, Han C-Z, Du D-Y. Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction. Atherosclerosis. 1990;82:253-259.[Medline] [Order article via Infotrieve]
18. Hearn JA, DeMaio SJ, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol. 1990;66:1176-1180.[Medline] [Order article via Infotrieve]
19.
Sandkamp M, Funke H, Schulte H, Kohler E, Assmann
G. Lipoprotein(a) is an independent risk factor for myocardial
infarction at a young age. Clin Chem. 1990;36:20-23.
20. Maher VMG, Kitano Y, Neuwirth C, Kehely A, Thompson GR. Lp(a) and coronary atherosclerosis in familial hypercholesterolemia. Arterioscler Thromb. 1991;11:1520. Abstract.
21. Genest J, Jenner JL, McNamara JR, Ordovas JM, Siberman SR, Wilson PWF, Schaefer EJ. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol. 1991;67:1039-1045.[Medline] [Order article via Infotrieve]
22.
Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM,
Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer
EJ. Familial lipoprotein disorders in patients with premature
coronary artery disease. Circulation. 1992;85:2025-2033.
23. Genest JJ, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DS, Schaefer EJ. Lipoprotein cholesterol, apolipoproteins A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.[Abstract]
24. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.[Abstract]
25.
Labeur C, De Bacquer D, De Backer G, Vincke J,
Muyldermans L, Vandekerckhove Y, Van der Stichele E, Rosseneu M.
Plasma lipoprotein(a) values and severity of coronary artery
disease in a large population of patients undergoing coronary
angiography. Clin Chem. 1992;38:2261-2266.
26.
Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W,
Tyroler HA, Wu K, Heiss G. Lipoprotein(a) as a risk factor for
preclinical atherosclerosis. Arterioscler
Thromb. 1993;13:826-833.
27. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lesperance J, Campeau L. Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 1993;72:1215-1219.[Medline] [Order article via Infotrieve]
28. Wu JH, Kao JT, Wen MS, Wu D. Coronary artery disease risk predicted by plasma concentrations of high density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) in a general Chinese population. Clin Chem. 1993;39:209-212.[Abstract]
29. Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis. 1993;98:139-151.[Medline] [Order article via Infotrieve]
30.
Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen
M, Vartiainen E, Myllyla G, Ehnholm C. Haemostatic factors and
prevalent coronary heart disease: the FINRISK Haemostasis
Study. Eur Heart J. 1994;15:1293-1299.
31. Parlavecchia M, Pancaldi A, Taramelli R, Valsania P, Galli L, Pozza G, Chierchia S, Ruotolo G. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol. 1994;74:346-351.[Medline] [Order article via Infotrieve]
32.
Farrer M, Game FL, Albers CJ, Neil AW, Winocour PH,
Laker MF, Adams PC, Alberti KGMM. Coronary artery
disease is associated with increased lipoprotein(a) concentrations
independent of the size of circulating apolipoprotein(a)
isoforms. Arterioscler Thromb. 1994;14:1272-1283.
33. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients: relationship with apolipoprotein(a) phenotypes. Diabetologia. 1994;37:585-591.[Medline] [Order article via Infotrieve]
34. Docci D, Manzoni G, Bilancioni R, Delvecchio C, Capponcini C, Baldrati L, Neri L, Feletti C. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs. 1994;17:41-45.[Medline] [Order article via Infotrieve]
35.
Cooke T, Sheahan R, Foley D, Reilly M, D'Arcy G,
Jauch W, Gibney M, Gearty G, Crean P, Walsh M. Lipoprotein(a) in
restenosis after percutaneous transluminal
coronary angioplasty and coronary artery
disease. Circulation. 1994;89:1593-1598.
36.
Budde T, Fechtrup C, Bosenberg E, Vielhauer C,
Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a)
levels correlate with number, severity, and length extension of
coronary lesions in male patients undergoing coronary
arteriography for clinically suspected coronary
atherosclerosis. Arterioscler
Thromb. 1994;14:1730-1736.
37. Kario K, Matsuo T, Imiya M, Kayaba K, Kuroda T, Nago N, Matsuo H, Shimada K. Close relation between lipoprotein(a) levels and atherothrombotic disease in Japanese subjects >75 years of age. Am J Cardiol. 1994;73:1187-1190.[Medline] [Order article via Infotrieve]
38. Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M. Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long term n-3 fatty acid supplementation. Scand J Clin Lab Invest. 1995;55:295-300.[Medline] [Order article via Infotrieve]
39. Koh KK, Lee KH, Cho SK, Kim SS, Kim JJ, Lee YH. Association of lipoprotein levels with atherosclerotic changes in patients with coronary artery spasm and insignificant coronary artery stenosis. Coron Artery Dis. 1995;6:235-239.[Medline] [Order article via Infotrieve]
40. Maranhão RC, Vinagre CG, Arie S, Guimaraes JB, da Luz P, Bellotti G, Pileggi F. Lipoprotein (a) in subjects with or without coronary artery disease: relation to clinical history and risk factors. Braz J Med Biol Res. 1995;28:439-446.[Medline] [Order article via Infotrieve]
41. Orem A, Deger O, Kulan K, Onder E, Kiran E, Uzunosmanoglu D. Evaluation of lipoprotein(a) [Lp(a)] as a risk factor for coronary artery disease in the Turkish population. Clin Biochem. 1995;28:171-173.[Medline] [Order article via Infotrieve]
42. Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M. Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease. Coron Artery Dis. 1995;6:397-402.[Medline] [Order article via Infotrieve]
43. Stiel GM, Reblin T, Buhrlen M, Lattermann A, Nienaber CA. Differences in lipoprotein(a) and apolipoprotein(a) levels in men and women with advanced coronary atherosclerosis. Coron Artery Dis. 1995;6:347-350.[Medline] [Order article via Infotrieve]
44.
Kraft HG, Lingenhel A, Köchl S, Hoppichler F,
Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann
G. Apolipoprotein(a) kringle IV repeat number predicts risk for
coronary heart disease. Arterioscler Thromb Vasc
Biol. 1996;16:713-719.
45.
Bartens W, Nauck M, Schollmeyer P, Wanner C.
Elevated lipoprotein(a) and fibrinogen serum levels increase the
cardiovascular risk in continuous ambulatory peritoneal
dialysis patients. Perit Dial Int. 1996;16:27-33.
46.
Sunayama S, Daida H, Mokuno H, Miyano H, Yokoi H, Lee
YJ, Sakurai H, Yamaguchi H. Lack of increased coronary
atherosclerotic risk due to elevated lipoprotein(a) in women 
55 years
of age. Circulation. 1996;94:1263-1268.
47. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J. 1990;301:1248-1251.
48. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.[Medline] [Order article via Infotrieve]
49.
Cressman MD, Heyka RJ, Paganini EP, O'Neil J,
Skibinski CI, Hoff HF. Lipoprotein (a) is an independent risk
factor for cardiovascular disease in hemodialysis
patients. Circulation. 1992;86:475-482.
50.
Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner
JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective
investigation of elevated lipoprotein(a) detected by electrophoresis
and cardiovascular disease in women: the Framingham
Heart Study. Circulation. 1994;90:1688-1695.
51.
Wang XL, Tam C, McCredie RM, Wilcken DEL.
Determinants of severity of coronary artery disease in
Australian men and women. Circulation. 1994;89:1974-1981.
52. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.[Medline] [Order article via Infotrieve]
53.
Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR,
Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI.
Lipoprotein(a) levels and risk of coronary heart disease in
men: the Lipid Research Clinics Coronary Primary Prevention
Trial. JAMA. 1994;271:999-1003.
54. Cantin B, Moorjani S, Despres JP, Dagenais GR, Lupien PJ. Lp(a) ischemic heart disease: the Quebec Cardiovascular Study. J Am Coll Cardiol. 1994;(Feb suppl):482A. Abstract.
55. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.[Medline] [Order article via Infotrieve]
56. Alfthan G, Pekkanen J, Jauhainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.[Medline] [Order article via Infotrieve]
57.
Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman
LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma
lipoprotein(a) and coronary heart disease in men aged 55 years
and younger: a prospective study. JAMA. 1996;276:544-548.
58. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.[Medline] [Order article via Infotrieve]
59.
Wild SH, Fortmann SP, Marcovina SM. A
prospective case-control study of lipoprotein(a) levels and apo(a) size
and risk of coronary heart disease in Stanford Five-City
Project participants. Arterioscler Thromb Vasc
Biol. 1997;17:239-245.
60. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Maninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.[Medline] [Order article via Infotrieve]
61.
Ridker PM, Hennekens CH, Stampfer MJ. A
prospective study of lipoprotein(a) and the risk of myocardial
infarction. JAMA. 1993;270:2195-2199.
62.
Moliterno DJ, Jokinen EV, Miserez AR, Lange RA,
Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association
between plasma lipoprotein(a) concentrations and the presence or
absence of coronary atherosclerosis in African
Americans. Arterioscler Thromb Vasc Biol. 1995;15:850-855.
63. Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis. 1993;99:87-95.[Medline] [Order article via Infotrieve]
64. Watts GF, Jackson P, Mandalia S, Brunt JNH, Lewis ES, Coltart DJ, Lewis B. Nutrient intake and progression of coronary artery disease. Am J Cardiol. 1994;73:328-332.[Medline] [Order article via Infotrieve]
65.
Tamura A, Watanabe T, Mikuriya Y, Nasu M.
Serum lipoprotein(a) concentrations are related to coronary
disease progression without new myocardial infarction. Br
Heart J. 1995;74:365-369.
66.
Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U,
Hamm CW. Rapid angiographic progression of coronary
artery disease in patients with elevated lipoprotein(a).
Circulation. 1995;91:948-950.
67.
Hoff HF, Beck GJ, Skibinski CI, Jurgens G, O'Neil J,
Kramer J, Lytle B. Serum Lp(a) level as a predictor of vein
graft stenosis after coronary artery bypass surgery in
patients. Circulation. 1988;77:1238-1244.
68. Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Grønseth K, Berg K, Malinow MR. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol. 1994;74:1099-1102.[Medline] [Order article via Infotrieve]
69. Michishita I, Shibazaki Y, Umeda K, Mizuno K, Watanabe S, Genda A. Serum lipoprotein (a) as a restenosis risk factor after percutaneous transluminal coronary angioplasty. Arteriosclerosis. 1991;11:1423. Abstract.
70. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SB, Lembo NJ, Roubin GS, Sgoutas DS. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1992;69:736-739.[Medline] [Order article via Infotrieve]
71. Tenda K, Saikawa T, Maeda T, Sato Y, Niwa H, Inoue T, Yonemochi H, Maruyama T, Shimoyama N, Aragaki S,. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J. 1993;57:789-795.[Medline] [Order article via Infotrieve]
72. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsumi Y, Yamada N, Noma A, Yamaguchi H, Group L-DLAARTL-A. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol. 1994;73:1037-1040.[Medline] [Order article via Infotrieve]
73. Yamaguchi H, Lee YJ, Daida H, Yokoi H, Miyano H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F,. Effectiveness of LDL apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL apheresis angioplasty restenosis trial (L ART). Chem Phys Lipids. 1994;68:399-403.
74. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J. 1995;130:1168-1173.[Medline] [Order article via Infotrieve]
75.
Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM,
Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk
factor for clinical recurrence after coronary balloon
angioplasty. Circulation. 1995;91:1403-1409.
76. Tsurumi Y, Nagashima H, Ichikawa K, Sumiyoshi T, Hosoda S. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol. 1995;26:1242-1250.[Abstract]
77.
Zenker G, Koltringer P, Bone G, Niederkorn K,
Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for
cerebrovascular disease. Stroke. 1986;17:942-945.
78.
Cambillau M, Simon A, Amar J, Giral P, Atger V,
Segond P, Levenson J, Merli I, Megnien JL, Plainfosse MC,. Serum Lp(a)
as a discriminant marker of early atherosclerotic plaque at three
extracoronary sites in hypercholesterolemic
men: the PCVMETRA Group. Arterioscler Thromb. 1992;12:1346-1352.
79. Tato F, Keller C, Schuster H, Spengel F, Wolfram G, Zollner N. Relation of lipoprotein(a) to coronary heart disease and duplex sonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis. 1993;101:69-77.[Medline] [Order article via Infotrieve]
80.
Mölgaard J, Klausen IC, Lassvik C, Faergeman O,
Gerdes LU, Olsson AG. Significant association between
low-molecular-weight apolipoprotein(a) isoforms and intermittent
claudication. Arterioscler Thromb. 1992;12:895-901.
81. Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg. 1993;7:446-451.[Medline] [Order article via Infotrieve]
82.
Valentine RJ, Grayburn PA, Vega GL, Grundy SM.
Lp(a) lipoprotein is an independent, discriminating risk factor for
premature peripheral atherosclerosis among
white men. Arch Intern Med. 1994;154:801-806.
83.
Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS,
Berenson GS. Racial (black-white) differences in serum
lipoprotein(a) distribution and its relation to parental myocardial
infarction in children: Bogalusa Heart Study.
Circulation. 1991;84:160-167.
84. Marquez A, Mendoza S, Carrasco H, Hamer T, Glueck CJ. High lipoprotein(a) in children from kindreds with parental premature myocardial infarction. Pediatr Res. 1993;34:670-674.[Medline] [Order article via Infotrieve]
85. Wilcken DE, Wang XL, Greenwood J, Lynch J. Lipoprotein(a) and apolipoproteins B and A 1 in children and coronary vascular events in their grandparents. J Pediatr. 1993;123:519-526.[Medline] [Order article via Infotrieve]
86.
Badenhop RF, Wang XL, Wilcken DE.
Angiotensin-converting enzyme genotype in children
and coronary events in their grandparents.
Circulation. 1995;91:1655-1658.
87.
Bailleul S, Couderc R, Rossignol C, Fermanian J,
Boutouchent F, Farnier MA, Etienne J. Lipoprotein(a) in
childhood: relation with other atherosclerosis risk
factors and family history of atherosclerosis.
Clin Chem. 1995;41:241-245.
88.
Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao
X-Q, Albers JJ. Effects of lowering elevated LDL
cholesterol on the cardiovascular risk of
lipoprotein(a). JAMA. 1995;274:1771-1774.
89. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest. 1992;90:52-60.
90. DeMeester CA, Bu X, Puppione D, Gray RM, Lusis AJ, Rotter JI. Genetic variation in lipoprotein(a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein(a) gene locus. Hum Genet. 1995;56:675-679.
91. Maher MG, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-235.[Medline] [Order article via Infotrieve]
92. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chron Dis. 1986;39:809-821.[Medline] [Order article via Infotrieve]
93.
Williams RR, Hunt SC, Barlow GK, Chamberlain RM,
Weinberg AD, Cooper HP, Carbonari JP, Gotto AM. Health Family
Trees: a tool for finding and helping young family members of
coronary and cancer prone pedigrees in Texas and Utah.
Am J Public Health. 1988;78:1283-1286.
94.
Higgins M, Province M, Heiss G, Eckfeldt J, Ellison
RC, Folson AR, Rao DC, Sprafka JM, Williams R. NHLBI Family
Heart Study: objectives and design. Am J
Epidemiol. 1996;143:1219-1228.
95.
Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL,
Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel J-M, Kuida H.
Familial dyslipidemic hypertension: evidence from 58 Utah
families for a syndrome present in approximately 12% of patients
with essential hypertension. JAMA. 1988;259:3579-3586.
96.
Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent
GM, Williams RR. Higher plasma homocyst(e)ine and increased
susceptibility to adverse effects of low folate in early familial
coronary artery disease. Arterioscler Thromb Vasc
Biol. 1995;15:1314-1329.
97.
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM,
Williams RR. Higher serum bilirubin is associated with decreased
risk for early familial coronary artery disease.
Arterioscler Thromb Vasc Biol. 1996;16:250-255.
98. Marcovina SM, Levine DM, Lippi G. Lipoprotein(a): structure, measurement, and clinical significance. In: Rifai N, Warnick GR, eds. Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC: AACC Press; 1994:235-263.
99. Lipid Research Clinics Program. Manual of Laboratory Operations. Washington, DC: 1974. US Dept of Health, Education, and Welfare publication NIH 75-628.
100.
Wu LL, Warnick GR, Wu JT, Williams RR, Lalouel
JM. A rapid micro-scale procedure for determination of the total
lipid profile. Clin Chem. 1989;35:1486-1491.
101. Rodriguez CR, Seman LJ, Ordovas JM, Jenner J, Genest MSJ, Wilson PWF, Schaefer EJ. Lipoprotein(a) and coronary heart disease. Chem Phys Lipids. 1994;67/68:389-398.
102. Usher DC, Swanson C, Rader DJ, Krämer J, Brewer HB. A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. Chem Phys Lipids. 1994;67/68:243-248.
103.
Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur
VP. Effect of the number of apolipoprotein(a) kringle 4 domains
on immunochemical measurements of lipoprotein(a). Clin
Chem. 1995;41:246-255.
104. Kronenberg F, Lobentanz EM, Konig P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein, apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res. 1994;35:1318-1328.[Abstract]
105. Lovejoy K, Bachorik PS. Lp(a) measurements may be unreliable in stored sera. Circulation. 1994;90(suppl I):I-504. Abstract.
106.
Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B,
Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of
hyperhomocyst(e)inemia in patients with peripheral
arterial occlusive disease. Circulation. 1989;79:1180-1188.
107.
Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams
RR, Hopkins PN. Plasma homocyst(e)ine as a risk factor for early
familial coronary artery disease. Clin Chem. 1994;40:552-561.
108. Rothman KJ. Modern epidemiology. Boston. Mass: Little, Brown, and Company; 1986.
109. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 1993;223:73-82.[Medline] [Order article via Infotrieve]
110. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992;52:95-101.[Medline] [Order article via Infotrieve]
111. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.[Medline] [Order article via Infotrieve]
112. Klezovitch O, Scanu AM. Heterogeneity of lipoprotein (a): growing complexities. Curr Opin Lipidol. 1995;6:223-228.[Medline] [Order article via Infotrieve]
113.
Loscalzo J, Weinfeld M, Fless GM, Scanu AM.
Lipoprotein (a), fibrin binding, and plasminogen
activation. Arteriosclerosis. 1990;10:240-245.
114.
Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano
E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound
tissue-type plasminogen activator: in vitro
studies in a plasma milieu. Arterioscler Thromb. 1991;11:629-638.
115. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;256-259.
116.
Bihari-Varga M, Gruber E, Rotheneder M, Zechner R,
Kostner GM. Interaction of lipoprotein Lp(a) and low density
lipoprotein with glycosaminoglycans from human
aorta. Arteriosclerosis. 1988;8:851-857.
117.
Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a)
inhibits the generation of transforming growth factor ß: an
endogenous inhibitor of smooth muscle cell
migration. J Cell Biol. 1991;113:1439-1445.
118. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-ß is inhibited in apolipoprotein(a) transgenic mice. Nature. 1994;370:460-462.[Medline] [Order article via Infotrieve]
119. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Cauhan A. The serum concentration of active transforming growth factor-ß is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.[Medline] [Order article via Infotrieve]
120. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a): a comparison with low density lipoproteins. Biochim Biophys Acta. 1991;1081:65-74.[Medline] [Order article via Infotrieve]
121.
Haberland MD, Fless GM, Scanu AM, Fogelman AM.
Malondialdehyde modification of lipoprotein(a) produces avid uptake by
human monocyte-macrophages. J Biol
Chem. 1992;267:4143-4151.
122.
Bottalico LA, Keesler GA, Fless GM, Tabas I.
Cholesterol loading of macrophages leads to marked
enhancement of native lipoprotein(a) and apoprotein(a) internalization
and degradation. J Biol Chem. 1993;268:8569-8573.
123.
Moliterno DJ, Lange RA, Meidell RS, Willard JE,
Leffert CC, Gerard RD, Boerwinkle E, Hobbs HH, Hillis LD.
Relation of plasma lipoprotein(a) to infarct artery patency in
survivors of myocardial infarction. Circulation. 1993;88:935-940.
124. Koltringer P, Langsteger W, Lind P, Reisecker F, Eber O, Jurgens G. Increased mortality in patients with elevated serum levels of lipoprotein(a). Arterioscler Thromb. 1991;11:1518. Abstract.
This article has been cited by other articles:
 |
|
 |
|
  E. A Enas, A. Senthilkumar, C. Vinod, and N. Puthumana Dyslipidaemia among Indo-Asians strategies for identification and management The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 81 - 90. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Friehs, A. M. Moran, C. Stamm, Y.-H. Choi, D. B. Cowan, F. X. McGowan, and P. J. del Nido Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury Ann. Thorac. Surg., June 1, 2004; 77(6): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Muller, A. S. Lindman, A. Blomfeldt, I. Seljeflot, and J. I. Pedersen A Diet Rich in Coconut Oil Reduces Diurnal Postprandial Variations in Circulating Tissue Plasminogen Activator Antigen and Fasting Lipoprotein (a) Compared with a Diet Rich in Unsaturated Fat in Women J. Nutr., November 1, 2003; 133(11): 3422 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Meinertz, K. Nilausen, and J. Hilden Alcohol-Extracted, but Not Intact, Dietary Soy Protein Lowers Lipoprotein(a) Markedly Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 312 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rizos and D. P Mikhailidis Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res, November 1, 2001; 52(2): 199 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kareinen, L. Viitanen, P. Halonen, S. Lehto, and M. Laakso Cardiovascular Risk Factors Associated With Insulin Resistance Cluster in Families With Early-Onset Coronary Heart Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1346 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Fodor, J. J. Frohlich, J. J.G. Genest Jr., P. R. McPherson, and for the Working Group on Hypercholesterolemia and Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias Can. Med. Assoc. J., May 16, 2000; 162(10): 1441 - 1447. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, J. A. Milberg, K. Robinson, G. L. Pearce, D. W. Jacobsen, and D. L. Sprecher Homocysteine and Lipoprotein(a) Interact to Increase CAD Risk in Young Men and Women Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 493 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kronenberg, M. F. Kronenberg, S. Kiechl, E. Trenkwalder, P. Santer, F. Oberhollenzer, G. Egger, G. Utermann, and J. Willeit Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis : Prospective Results From the Bruneck Study Circulation, September 14, 1999; 100(11): 1154 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Enas and S. T. Jacob Emerging Noninvasive Biochemical Measures: Potential Explanation for Ethnic Differences in Cardiovascular Risk Arch Intern Med, August 9, 1999; 159(15): 1812 - 1813. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Rainwater, C. A. McMahan, G. T. Malcom, W. D. Scheer, P. S. Roheim, H. C. McGill Jr, and J. P. Strong Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth : Apolipoprotein Concentrations Do Not Materially Improve Prediction of Arterial Lesions in PDAY Subjects Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 753 - 761. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||